shutterstock_1125283274_panuwach
panuwach / Shutterstock.com
23 April 2019Americas

Charpentier granted new CRISPR/Cas9 patent

ERS Genomics has announced a new CRISPR/Cas9 US patent for use of the gene-editing technology in a single guide format.

The company licenses the rights to CRISPR patents co-owned by French microbiologist Emmanuelle Charpentier.

The US Patent and Trademark Office (USPTO) issued the patent (US number 10,266,850) to Charpentier, the Regents of the University of California and the University of Vienna.

In  a press release issued today, April 23, ERS Genomics said that the patent “covers uses in any cellular or non-cellular environment and delivery of the CRISPR/Cas9 components by any methods”.

According to the release, the patent was the subject of an interference proceeding with the Broad Institute, a Harvard University and Massachusetts Institute of Technology affiliate which has previously rivalled Charpentier for ownership of CRISPR patent rights.

Eric Rhodes, CEO of ERS Genomics, said that the USPTO had “released the claims from the interference as they were broader in scope than the claims of the Broad Institute”.

“The scope of the patent includes any cellular or non-cellular environment, making it applicable not only in vitro but also across living plants, animals, and human cells,” Rhodes added.

It is the fourth CRISPR/Cas9 US patent granted to Charpentier, the University of California and the University of Vienna.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.
Biotechnology
28 May 2019   The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Genetics
4 June 2019   Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.

More on this story

Genetics
4 June 2019   Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.
Biotechnology
28 May 2019   The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Biotechnology
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.

More on this story

Genetics
4 June 2019   Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.
Biotechnology
28 May 2019   The US Patent and Trademark Office has issued a new CRISPR/Cas9 patent to the University of California, the University of Vienna and microbiologist Emmanuelle Charpentier.
Biotechnology
14 December 2018   ERS Genomics has signed a deal with Swiss company Lonza Pharma & Biotech to provide access to CRISPR/Cas9 technology.